Description

(Neuroactive Peptide Therapy for Sexual Arousal and Desire Enhancement – Subcutaneous Injection)

High-Potency Central Arousal Therapy for Men and Women

Bremelanotide (PT-141) is a neuropeptide-based medication designed to address sexual desire and arousal dysfunction in both women and men. This 10 mg injectable dose in a 2 mL sterile vial delivers a powerful, fast-acting formulation that stimulates key neuroreceptors responsible for sexual motivation, arousal response, and intimate readiness—regardless of vascular or hormonal limitations.

Originally developed for sexual dysfunction, Bremelanotide is now recognized as a centrally acting therapeutic agent, targeting the brain’s melanocortin system rather than peripheral blood vessels. It is particularly valuable in cases of hypoactive sexual desire disorder (HSDD), psychogenic erectile dysfunction (ED), and age-related decline in sexual motivation.

Product Overview

• Active Ingredient: Bremelanotide (PT-141)

• Strength: 10 mg total per vial

• Volume: 2 mL (5 mg/mL concentration)

• Formulation: Sterile injectable solution

• Administration: Subcutaneous injection

• Storage: Refrigerate at 2–8°C (36–46°F); protect from light

• Use: Physician-directed therapy for sexual dysfunction and libido support

What Makes Bremelanotide Unique?

Bremelanotide is a melanocortin receptor agonist, specifically targeting MC4R receptors in the hypothalamus. Its mechanism of action differs significantly from PDE5 inhibitors (e.g., sildenafil or tadalafil), which only improve blood flow. PT-141 instead modulates central arousal pathways, helping individuals regain sexual desire, intimacy interest, and arousal—even when physical stimulation is limited or ineffective.

This makes Bremelanotide an ideal choice for:

• Patients unresponsive to PDE5 inhibitors

• Individuals with psychogenic or neurogenic sexual dysfunction

• Women experiencing low libido unrelated to hormonal imbalances

• Couples seeking to enhance intimacy naturally, with medically guided support

Mechanism of Action

• Stimulates MC4R receptors in the brain

• Triggers sexual arousal pathways without requiring direct genital stimulation

• Increases dopamine-related arousal signals in both men and women

• Onset of action: typically within 30–60 minutes

• Duration of effect: up to 6–12 hours depending on dose and metabolism

Indications for Use

This high-potency injectable is indicated for:

• Hypoactive Sexual Desire Disorder (HSDD) in pre- and postmenopausal women

• Erectile Dysfunction (ED) with a psychogenic or mixed origin

• Sexual arousal difficulties due to fatigue, medication side effects, or relationship stress

• Enhancement of libido and sexual responsiveness in healthy individuals under supervision

• Adjunctive support in hormone replacement therapy (HRT) protocols where libido remains low

Bremelanotide may also benefit patients with SSRI-induced sexual dysfunction, a common side effect of antidepressant therapy.

Dosing and Administration

• Standard Dose: 1.25–2 mg subcutaneously, 30 to 60 minutes before anticipated intimacy

• Injection Site: Abdomen or upper thigh, using a small-gauge insulin syringe

• Maximum Dose: No more than 1 dose per 24-hour period, and 8 doses per month

• Onset: Begins working in 30–60 minutes

• Duration: A single dose may last up to 12 hours

The 10 mg vial can provide multiple doses depending on the patient’s titrated regimen.

Safety and Tolerability

Bremelanotide has demonstrated a strong safety profile in clinical trials and real-world use. However, as a neuroactive compound, it may cause mild systemic effects in some patients.

Common side effects include:

• Nausea (most frequent; dose-dependent)

• Flushing or warmth

• Headache or dizziness

• Mild increase in blood pressure (transient)

• Injection site irritation (rare)

These effects are generally short-lived and subside without intervention.

Contraindications

Do not use in:

• Individuals with uncontrolled hypertension or cardiovascular disease

• Known allergy to melanocortin analogues

• Pregnant or breastfeeding women (safety has not been established)

• Concurrent use with alpha-adrenergic agonists or CNS stimulants unless directed

Monitor patients with a history of migraine, hypotension, or sensitive vasculature.

Storage and Handling

• Store refrigerated at 2–8°C (36–46°F)

• Do not freeze

• Use sterile technique with each draw from the vial

• Vial should be used within 30 days of first puncture, unless otherwise directed

Why Choose Bremelanotide Injectable?

• Central nervous system action = deeper arousal activation

• Effective in both men and women

• Works even when vascular therapies fail

• Injectable format offers fast, high-bioavailability delivery

• Ideal for patients needing higher potency or precision-titrated doses

Summary

Bremelanotide (PT-141) – 10 mg Injectable in 2 mL Vial provides a powerful, centrally acting solution for individuals facing libido loss, arousal difficulties, or sexual performance concerns. Its ability to stimulate desire neurologically, without relying on physical stimulation or hormonal change, makes it a standout therapy in the evolving field of sexual wellness and intimacy medicine. Supervised and customized dosing ensures safe, confident use for optimized results.